CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases. Our team has over 20 years’ experience in oncology and molecular cell biology and are using our expertise and experience in these areas to develop novel innovative treatments that will enhance the effectiveness of standard-of-care therapies in oncology and other inflammatory conditions.
CV6 Therapeutics is dedicated to the development of novel innovative therapeutics to enhance the effectiveness of the most widely used, standard-of-care therapies and to improve the lives of patients with cancer and inflammatory diseases.
Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]Find Out More